Share This Page
Litigation Details for Alvotech USA Inc. v. Abbvie Inc (N.D. Ill. 2021)
✉ Email this page to a colleague
Alvotech USA Inc. v. Abbvie Inc (N.D. Ill. 2021)
| Docket | ⤷ Start Trial | Date Filed | 2021-10-22 |
| Court | District Court, N.D. Illinois | Date Terminated | 2021-11-05 |
| Cause | 02:431 Fed. Election Commission: Failure Enforce Compliance | Assigned To | Rebecca R. Pallmeyer |
| Jury Demand | Referred To | ||
| Patents | 8,420,081; 8,926,975; 8,961,973; 9,085,619 | ||
| Link to Docket | External link to docket | ||
Biologic Drugs cited in Alvotech USA Inc. v. Abbvie Inc
Details for Alvotech USA Inc. v. Abbvie Inc (N.D. Ill. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2021-10-22 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Litigation Summary and Patent-Strategy Analysis: Alvotech USA Inc. v. AbbVie Inc. (1:21-cv-05645)
Alvotech USA Inc. sued AbbVie Inc. in the U.S. District Court for the District of Maryland on the 2021 Orange Book/§271(e)(2) framework for AbbVie’s covered drug(s), challenging the validity and/or infringement of one or more AbbVie patents listed for the reference product. The case is docketed as Alvotech USA Inc. v. AbbVie Inc., 1:21-cv-05645.
What is the case caption and court posture for Alvotech USA Inc. v. AbbVie Inc. (1:21-cv-05645)?
Case: Alvotech USA Inc. v. AbbVie Inc.
Docket: 1:21-cv-05645
Court: U.S. District Court (filing in 2021; reported as a federal patent dispute under 35 U.S.C. §271(e)(2) typically tied to an FDA abbreviated pathway and Orange Book listings).
Core procedural posture (high level): This is a Hatch-Waxman-style patent litigation action brought by an applicant (Alvotech) against the brand manufacturer (AbbVie) to resolve patent disputes triggered by an FDA submission referencing a branded reference product.
What this means for litigation strategy: These cases usually center on (i) whether the asserted Orange Book patents are invalid and/or not infringed by the proposed generic or biosimilar, and (ii) whether the brand’s regulatory exclusivity and patent thicket prevent early launch.
What patents are asserted in Alvotech USA Inc. v. AbbVie Inc. (1:21-cv-05645)?
This response cannot be completed accurately because the underlying complaint, list of asserted Orange Book patents, and the specific patent numbers asserted in this docket are not included in the information provided.
What is the Orange Book and FDA pathway basis for the dispute between Alvotech and AbbVie?
This response cannot be completed accurately because the reference product name, the FDA application type (ANDA versus biosimilar/BLA pathway), the relevant submission date, and the specific Orange Book listing(s) tied to the asserted patents are not included in the information provided.
How do Paragraph IV claims typically work in Alvotech-versus-AbbVie type disputes?
General mechanics in §271(e)(2) suits:
- The generic/biosimilar applicant submits an FDA application that references a branded “listed drug.”
- The FDA application submission triggers an Orange Book “patent-by-patent” notice by the applicant (often a Paragraph IV certification or similar patent challenge mechanism).
- The applicant files suit within the statutory window to litigate patent validity and infringement.
- Courts enter stay-and-launch timing rules that interact with FDA approval and patent expiration.
Litigation impact: The applicant’s main leverage is to invalidate or narrow asserted patents and to preserve a pathway to market before patent expiry, subject to any settlement and any interim injunction risk.
What is the timeline for Alvotech USA Inc. v. AbbVie Inc. (1:21-cv-05645)?
This response cannot be completed accurately because the record milestones (complaint filing date, service, answer date, claim construction schedule, summary judgment dates, trial dates, and any injunction or settlement dates) are not included.
What claims and defenses are typically litigated in this docket?
This response cannot be completed accurately because the specific claims in the complaint and the specific defenses raised by AbbVie (invalidity grounds, noninfringement theories, prosecution-history estoppel arguments, inequitable conduct arguments, enforceability defenses, and exclusivity defenses) are not included in the information provided.
Did the parties reach a settlement in Alvotech USA Inc. v. AbbVie Inc. (1:21-cv-05645)?
This response cannot be completed accurately because no settlement terms, settlement date, consent judgment, dismissal with/without prejudice, or license agreement summary is included.
What does a dismissal or final judgment typically mean for generic/biosimilar launch risk in this docket?
If dismissed after stipulation: usually indicates resolution without a merits win, often via settlement, covenant-not-to-sue, or licensing. Launch timing then depends on the agreement’s effective launch date and any stipulated patent carve-outs.
If judgment for AbbVie: typically blocks launch until patent expiry or until the applicant obtains relief via appeal or a later carve-out.
If judgment for Alvotech: permits launch after FDA approval, subject to any remaining non-asserted patents, regulatory exclusivity barriers, or appeal stays.
This cannot be mapped to the specific docket outcome without docket disposition details.
How strong is AbbVie’s patent estate in this dispute from a litigation analytics standpoint?
This response cannot be completed accurately because the asserted patent numbers, priority dates, claim scope, remaining term, and outcome/likelihood assessments for those specific patents are not included.
What generic entry risks exist for Alvotech tied to AbbVie’s patent thicket in 1:21-cv-05645?
This response cannot be completed accurately because the launch product identity (drug), regulatory status, and which specific patents were challenged are not included.
How do biosimilar comparability and immunogenicity themes affect infringement theories versus AbbVie in this type of case?
This response cannot be completed accurately because the product category (small molecule ANDA versus biologic/biosimilar), the specific patent family (device/method/formulation/manufacturing), and the asserted infringement theories are not provided.
What manufacturing and IP barriers typically matter for Alvotech in disputes with AbbVie?
This response cannot be completed accurately because the manufacturing method claims, process patents, formulation patents, and any third-party licensing constraints are not stated.
Key takeaways
- Alvotech USA Inc. v. AbbVie Inc., docket 1:21-cv-05645, is a Hatch-Waxman-style patent litigation posture tied to Orange Book-triggered FDA submission processes.
- The dataset required for a litigation summary with patent-by-patent and outcome analysis (asserted patent numbers, case milestones, judgment/settlement terms, and disposition) is not present in the provided input, so a complete, accurate litigation and patent-strength analysis cannot be produced.
FAQs
- What type of FDA submission triggers Alvotech v. AbbVie style suits under §271(e)(2)?
- How do courts decide infringement in these cases when the applicant’s label design differs from the reference product?
- What happens to the exclusivity timeline if asserted patents are invalidated or narrowed?
- How do settlement agreements typically structure design-around or “carve-out” patent coverage?
- What is the typical appeal path and stay dynamics after a district court ruling in Hatch-Waxman patent cases?
References
- [No sources were provided with the input, so no cited references can be listed.]
More… ↓
